ArticleTranslational lung cancer research2026
NOTCH4 as a driver of epithelial-mesenchymal transition, angiogenesis, and stromal remodeling in lung adenocarcinoma: integrated transcriptomic and protein-level validation.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although NOTCH4 plays an important role in tumor progression, its role in lung adenocarcinoma (LUAD) remains unclear. We examined the role of NOTCH4 in LUAD progression, its influence on the tumor microenvironment (TME), and its prognostic value, while isolating its specific contribution from those of NOTCH1 and NOTCH3. Methods: Gene set enrichment analysis (GSEA) and deconvolution-based TME analyses (xCell, ESTIMATE, and MCP-counter) were performed using three independent LUAD cohorts [The Cancer Genome Atlas (TCGA), OncoSG, and CPTAC]. Associations between NOTCH4 expression and epithelial-mesenchymal transition (EMT), angiogenesis, stromal remodeling, and survival were further validated using immunohistochemistry and histopathology in an independent LUAD cohort (n=347). Results: GSEA revealed significant enrichment of the EMT pathway in NOTCH4-high tumors across all three mRNA datasets. Deconvolution analyses demonstrated that NOTCH4-high tumors exhibited increased numbers of endothelial cells, fibroblasts, pericytes, and higher stromal and microenvironment scores, particularly in TCGA and OncoSG cohorts. In CPTAC, NOTCH4-high tumors showed enrichment of endothelial and fibroblast signatures, although global stromal and immune scores were not significantly different. In the independent cohort, after adjusting for NOTCH1 and NOTCH3 levels as covariates, NOTCH4 remained significantly associated with vimentin (Rho =0.160, P=0.007), microvessel density (MVD) (Rho =0.279, P<0.001), and stromal proportion (Rho =0.274, P<0.001), confirming its independent correlation with these markers. High NOTCH4 expression at both the mRNA and protein levels was associated with poorer overall survival (P=0.009 and P=0.009, respectively). Conclusions: Our findings provide the first systematic evidence that NOTCH4 is associated with EMT, angiogenesis, and stromal remodeling in LUAD, independent of NOTCH1 and NOTCH3 expression. By validating these associations at the protein level in an independent cohort, we highlight the translational potential of NOTCH4 as a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.